Replimune Group REPL Research and Development Incentives Receivable, Current
Research and Development Incentives Receivable, Current at other companies
Other financials
Where this comes from
Reported directly by Replimune Group in its filing.
Tagged under the XBRL concept repl:ResearchAndDevelopmentIncentivesReceivableCurrent.
The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Replimune Group's research and development incentives receivable, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Replimune Group's research and development incentives receivable, current?
- Replimune Group (REPL) reported research and development incentives receivable, current of $2.96M in Q4 2025.
- How has Replimune Group's research and development incentives receivable, current changed year-over-year?
- Replimune Group's research and development incentives receivable, current decreased by 3.6% year-over-year, from $3.07M to $2.96M.
- What is the long-term trend for Replimune Group's research and development incentives receivable, current?
- Over 4 years (2021 to 2025), Replimune Group's research and development incentives receivable, current has grown at a 6.0% compound annual growth rate (CAGR), from $2.95M to $3.73M.
- What does research and development incentives receivable, current mean?
- This metric represents the current portion of tax credits, government grants, or other financial incentives earned by the company for its research and development activities that are expected to be collected within one year. It reflects the anticipated cash inflow from regulatory or governmental bodies as a direct result of the company's investment in clinical-stage drug development. Tracking this balance provides insight into the company's ability to leverage non-dilutive funding sources to offset high R&D expenditures.